New structure announced for EMA

The European Medicines Agency has announced details of its new organizational structure. An agency statement said the changes fundamentally reorganize the EMA’s operations to support better its public and animal health mission, and its role as part of the European medicines regulatory system.

The new structure reflects a renewed focus on three key elements: how to better support the scientific work of the of the EMA committees; how to better share the knowledge and information the agency holds throughout the European Union medicines regulatory network; and how to better meet the need of the agency’s stakeholders and partners.

Guido Rasi, EMA executive director, said: “The changes announced today will reshape the EMA so that it is ready to handle future challenges and seize opportunities. My aim is to give our scientific committees the best possible support, alongside the expertise from the national agencies, to help them keep delivering high-quality, consistent opinions. These changes will enable us to use our resources more efficiently and effectively and ensures that the Agency is better prepared for future legislative and policy challenges.”